Agilent introduces NGS based solution for genetic disorders
Agilent Technologies Inc. recently announced the introduction of
Agilent OnePGT, a genome-wide, next-generation sequencing (NGS) solution for preimplantation genetic testing (PGT). OnePGT allows parallel detection of multiple monogenic disorders (PGT-M), translocations (PGT-SR), and aneuploidies (PGT-A) on a single biopsy. OnePGT guides the laboratory from biopsy material to a single comprehensive report in a matter of days. Empowered by Agilent’s Alissa platform, data analysis is streamlined by the optimized and verified pipelines, allowing automatic calling of genetic abnormalities with built-in quality control metrics and audit trail. This innovative solution provides fertility specialists the ability to more easily achieve comprehensive PGT data in which to support enhanced embryo ranking, identifying the best quality embryos for transfer. As the maternal age at conception increases, the chance of chromosomal abnormalities within the embryo also increase leading to lower implantation rates and increased rate of miscarriages.